Point72 Asia Singapore Pte. Ltd. Lowers Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Point72 Asia Singapore Pte. Ltd. trimmed its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 23.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,057 shares of the biopharmaceutical company’s stock after selling 2,749 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Theravance Biopharma were worth $77,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its position in shares of Theravance Biopharma by 66.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,583 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 3,824 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Theravance Biopharma during the 2nd quarter valued at $108,000. Gerber LLC acquired a new stake in shares of Theravance Biopharma during the 4th quarter worth $112,000. XTX Topco Ltd purchased a new position in shares of Theravance Biopharma in the 2nd quarter worth $129,000. Finally, State Board of Administration of Florida Retirement System boosted its holdings in Theravance Biopharma by 28.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 22,671 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 4,990 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Up 0.5 %

TBPH opened at $8.10 on Monday. The firm’s 50 day moving average is $8.52 and its 200-day moving average is $8.84. Theravance Biopharma, Inc. has a 52-week low of $7.44 and a 52-week high of $11.71. The firm has a market capitalization of $396.25 million, a P/E ratio of -9.42 and a beta of 0.24.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.25). The firm had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $15.81 million. Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. During the same period last year, the firm earned ($0.28) EPS. Equities analysts expect that Theravance Biopharma, Inc. will post -1.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TBPH has been the topic of a number of research reports. Leerink Partners downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $15.00 to $10.00 in a report on Tuesday, August 6th. TD Cowen reduced their price target on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Leerink Partnrs lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 6th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a report on Monday, September 16th. Finally, StockNews.com cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $13.75.

Insider Buying and Selling

In other Theravance Biopharma news, major shareholder Eli Samaha acquired 999,800 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were bought at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the acquisition, the insider now directly owns 9,511,150 shares of the company’s stock, valued at $74,186,970. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now owns 335,965 shares of the company’s stock, valued at approximately $3,023,685. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Eli Samaha purchased 999,800 shares of Theravance Biopharma stock in a transaction dated Wednesday, August 7th. The shares were bought at an average cost of $7.80 per share, for a total transaction of $7,798,440.00. Following the transaction, the insider now directly owns 9,511,150 shares of the company’s stock, valued at approximately $74,186,970. The disclosure for this purchase can be found here. Insiders own 6.90% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.